Nelarabine Injection

Shorla Oncology’s generic formulation of nelarabine, a treatment for T‑cell acute lymphoblastic leukemia (T‑ALL) and T‑cell lymphoblastic lymphoma (T‑LBL)

Ordering Information


Nelarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Please click here for the full Prescribing Information, including Boxed Warning.1


  • There are approximately 6,660 patients in the US diagnosed with acute lymphoblastic leukemia (ALL) per year2
  • The risk for developing ALL is highest among children under 5 years of age3
  • It is estimated that 12%-15% of pediatric patients diagnosed with ALL have T-cell acute lymphoblastic leukemia (T-ALL)4


One of a limited number of products used to treat these patients, Arranon® (nelarabine) injection suffered shortages in 2018 and 2019.5 Through key partner relationships, Shorla Oncology is helping to ensure that Nelarabine Injection will continue to be available for patients who need this treatment.

Image of pediatric patient who is currently being treated with Nelarabine Injection with a doctor


Shorla Oncology’s generic formulation of Nelarabine Injection is manufactured in Germany to our exacting standards. As the company’s first in-market product, maintaining the supply and ensuring access to nelarabine is our primary focus.


Adult dosage

The recommended adult dose of Nelarabine Injection is 1500 mg/m2 administered intravenously over 2 hours on Days 1, 3, and 5, repeated every 21 days. Administer Nelarabine Injection undiluted.

Pediatric dosage

The recommended pediatric dose of Nelarabine Injection is 650 mg/m2 administered intravenously over 1 hour daily for 5 consecutive days, repeated every 21 days. Administer Nelarabine Injection undiluted.

The recommended duration of treatment for adult and pediatric patients has not been clearly established. In clinical trials, treatment was generally continued until there was evidence of disease progression, the patient experienced unacceptable toxicity, the patient became a candidate for hematopoietic stem cell transplantation (HSCT), or the patient no longer continued to benefit from treatment.

Please see full Prescribing Information for more information on dosing and administration.


Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted to 15 °C to 30 °C (59 °F to 86 °F). Discard unused portion.

Nelarabine Injection Product Fact Sheet

Dosing information, billing codes, ordering information, and more—ready to download and print.

Image of Nelarabine Injection product fact sheet

Nelarabine Injection Product Fact Sheet

Dosing information, billing codes, ordering information, and more—ready to download and print.



Authorized Distributors

Amerisource Bergen logo Cardinal Health logo CuraScript logo
McKesson logo Morris & Dickson logo

Order Direct

Shorla Oncology representatives are available to assist you from 8 AM to 5 PM CST.

Icon of telephone

CALL844-9-SHORLA, option 2

Icon of FAX machine


Illustration representing contacting a representative

Contact a representative

For questions about Nelarabine Injection or to request an appointment, please email

Illustration representing requesting online information

Request medical information

Contact Shorla Oncology
Medical Information at medicalinfo or call 844-9-SHORLA

Illustration representing an reporting an adverse event

Report an adverse event

Please call Shorla Oncology at 844-9-SHORLA

The information contained on this page is intended for US audiences only.

All trademarks are the property of their respective owners.

References: 1. Nelarabine [prescribing information]. Cambridge, MA: Shorla Oncology; December 2022. 2. American Cancer Society. Cancer Facts & Figures, 2022. 3. American Cancer Society. About Acute Lymphocytic Leukemia. Accessed June 22, 2022. cancer/ acute-lymphocytic-leukemia/ about/ key-statistics.html 4. Raetz E, Teachey D. T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016(1):580-588. 5. Drug Shortages. Nelarabine Injection. Updated October 22, 2019. Accessed December 2, 2022.

SH-111-003 03/2023